Fig. 1From: Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patientsConsolidated Standards of Reporting Trials (CONSORT) diagram of patient flow through the studyBack to article page